CRISPR Therapeutics CRSP Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaboration Revenue | $1M-97.1% | $0-100% | $35M-82.5% | $35M-82.5% | $35M-87.0% | |
| Grant | $3.1M+16.0% | $3.51M+51.7% | $3.34M+18.0% | $3.05M+37.0% | $2.68M+56.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does CRISPR Therapeutics break its business down?
- CRISPR Therapeutics (CRSP) reports revenue by product across 2 parts — Collaboration Revenue and Grant. Each is extracted from the segment footnotes and tracked over time.
- Where does CRISPR Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in CRISPR Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
